Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma
NCT06271057Phase 2Recruiting
- Sponsor
- LYSARC
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golcadomide in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Primary endpoint: Complete metabolic response rate at 3 months. Started Jun 2024; status: recruiting.
02
Drugs
golcadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06271057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06271057.